Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10609/146896
Título : | Benzodiazepine and Z-drug use and the risk of developing dementia |
Autoría: | Torres-Bondia, Francisco-Ignacio Dakterzada, Farida Galván, Leonardo Buti, Miquel Besanson, Gaston Grill, Eric Buil Giné, Roman de Batlle, Jordi Piñol-Ripol, Gerard |
Otros: | Universitat Oberta de Catalunya (UOC) Santa Maria University Hospital Institut Català de la Salut |
Citación : | Francisco Torres-Bondia, Farida Dakterzada, Leonardo Galván, Miquel Buti, Gaston Besanson, Eric Grill, Roman Buil, Jordi de Batlle, Gerard Piñol-Ripoll, Benzodiazepine and Z-Drug Use and the Risk of Developing Dementia, International Journal of Neuropsychopharmacology, Volume 25, Issue 4, April 2022, Pages 261–268, https://doi.org/10.1093/ijnp/pyab073 |
Resumen : | Background: Benzodiazepines (BZDs) and Z-drugs (BZDRs) are among the most prescribed medications for anxiety and insomnia, especially among older adults. Our objective was to investigate the association between the use of BZDRs and the risk of dementia. Methods: A community-based retrospective cohort study was conducted based on the data available from 2002 to 2015 in Catalan Health Service. This cohort included all BZDR users (N = 83 138) and nonusers (N = 84 652) older than 45 years. A minimum 5-year lag window and an adjustment for psychiatric problems were applied for the data analysis. Results: The hazard ratio (HR) for the risk of incident dementia among BZDR users was 1.22 (95% CI = 1.15 to 1.31). This risk was not significant after adjusting the data confounding factors (HR = 1.01; 95% CI = 0.94 to 1.08). We observed a higher risk with short-to-intermediate half-life BZDs (HR = 1.11; 95% CI = 1.04 to 1.20) and Z-drugs (HR = 1.20; 95% CI = 1.07 to 1.33) than for intermediate-to-long half-life BZDs (HR = 1.01; 95% CI = 0.94 to 1.08). We demonstrated a higher risk of incident dementia (HR = 1.23; 95% CI = 1.07 to 1.41 and odds ratio = 1.38; 95% CI = 1.27 to 1.50, respectively) in patients who received 91 to 180 defined daily doses (DDDs) and >180 DDDs compared with patients who received <90 DDD. Regarding patient sex, the risk of dementia was higher in women than in men. Conclusion: We found that the incidence of dementia was not higher among all BZDR users. Short half-life BZDs and Z-drugs increased the risk of dementia at the highest doses, especially in female patients, showing a dose-response relationship. |
Palabras clave : | enfermedad del alzheimer benzodiacepina |
DOI: | https://doi.org/10.1093/ijnp/pyab073 |
Tipo de documento: | info:eu-repo/semantics/article |
Versión del documento: | info:eu-repo/semantics/publishedVersion |
Fecha de publicación : | 2-abr-2022 |
Licencia de publicación: | http://creativecommons.org/licenses/by-nc/4.0 |
Aparece en las colecciones: | Articles cientÍfics Articles |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Benzodiazepine and Z-Drug Use and the Risk of developing dementia.pdf | 348,68 kB | Adobe PDF | Visualizar/Abrir |
Comparte:
Los ítems del Repositorio están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.